Search
Cancel
Platform
Therapeutics
Therapeutics
Cell therapies
Pipeline
Partnerships
ioCells™
ioCells™
Discover ioCells
ioCells
ioWild Type Cells
ioDisease Model Cells
ioCRISPR-Ready Cells
Discover Custom ioCells
Custom ioCells
Custom ioDisease Model Cells
ioWild Type Cells
Glial cells
ioMicroglia | Female
ioMicroglia | Male
ioOligodendrocyte-like cells
Muscle cells
ioSkeletal Myocytes
Nerve cells
ioGABAergic Neurons
ioGlutamatergic Neurons
ioMotor Neurons
ioSensory Neurons
NEW! ioCRISPR-Ready Cells
CRISPR-Ready ioGlutamatergic Neurons
ioDisease Model Cells
Alzheimer's Disease
ioMicroglia APOE 4/4 C112R/C112R
See all >
Duchenne Muscular Dystrophy
ioSkeletal Myocytes DMD Exon 44 Deletion
See all >
ALS and FTD
ioGlutamatergic Neurons TDP‑43 M337V/M337V
See all >
Huntington's Disease
ioGlutamatergic Neurons HTT 50CAG/WT
See all >
Parkinson's and Gaucher Disease
ioGlutamatergic Neurons PRKN R275W/WT
See all >
News and Events
News and Events
News
View all
Topics
Article
CEO views
New product
News
Podcast
Press release
Talk
Events
View all
Resources
Resources
Resources
View all
General resources
Application notes
bits of bio
Case studies
Infographics
Posters
Publications
Talks
Videos
Video tutorials
Webinars
Product information
Brochures
User manuals
Protocol library
View all
CNS co-culture
ioGlutamatergic Neurons | ioMicroglia
CNS tri-culture MEA analysis
ioGlutamatergic Neurons | ioGABAergic Neurons | astrocytes
Cell culture and preparation
ioMicroglia cell detachment
Cell characterisation and assays
ioGABAergic Neurons ICC
ioGlutamatergic Neurons ICC
ioMicroglia cytokine release
ioOligodendrocyte-like cells ICC
ioSkeletal Myocytes ICC
Blog
View all articles
Browse topics
CEO views
Culture
Expert opinion
Leadership
Science
Technology
Sustainability
About
About
Our company
About us
Leadership and Boards
Sustainability
Work with us
Partners
Careers
Careers
Working at bit.bio
Open roles
How we hire
Employee spotlights
Contact
Search
Rewriting the story
of human health —
one cell at a time
Empowering biomedical innovation and a new generation of cures through precision reprogrammed human cells
Cell identity coding platform
Our platform has the ability to create any human cell type and to manufacture it at scale with precision and consistency.
Explore our platform
Therapeutics
Biology is our software, cells are our cures. Every cell type that we create has the potential to give rise to multiple next generation therapies.
Learn more
ioCells™
Precision reprogrammed human iPSC-derived cells for research and drug discovery.
Discover ioCells
Latest news
Article
bit.bio featured in Citeline by David Wild
09.05.2024
Published by Citeline
Read now
Article
BiotechTV and Brad Loncar visit to bit.bio
09.05.2024
Published by bit.bio
Read now
Press Release
Bi/ond and bit.bio collaboration generates 3D in vitro model for studying Duchenne Muscular Dystrophy (DMD)
30.04.2024
Published by bit.bio
Read now
Press Release
Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to lead fireside chat on programming human cells at SynBioBeta
29.04.2024
Published by bit.bio
Read now